Timeline & Milestones for Development Pathway

Development Path: TargaCell is seeking $3.5M to complete the Validation of Proof-of-Concept in mice without & with a surgically-induced heart attack, and manufacturing, leading within 20-24 months to IND-enabling safety and toxicology trials.

Progress: Proof-of-Concept data in a preclinical model show that our biologic products deliver, direct, and target 10x the number of stem cells to the heart without a catheter and retain these cells to enhance damaged tissue repair and restore function. TargaCell's proof-of-concept data support the following:

• Enhanced restoration of function will result from increased delivery & retention of cells to the site of damage.
• Our biologics prevent the off-target localization (entrapment) of stem cells in unwanted organs not targeted for repair.
• Extending our understanding of the mechanisms & identifying the specific molecules responsible for controlling cells' migration to an organ & preventing their entrapment will yield new intellectual property.